Jim Simons acquired 5.26M Corcept Therapeutics shares worth $621M. That's 0.81% of their equity portfolio (12th largest holding). The investor owns 4.70% of the outstanding Corcept Therapeutics stock. The first Corcept Therapeutics trade was made in Q1 2015. Since then Jim Simons bought shares 23 more times and sold shares on 22 occasions. The stake costed the investor $73.2M, netting the investor a gain of 748% so far.